See more : LAMF Global Ventures Corp. I (LGVCU) Income Statement Analysis – Financial Results
Complete financial analysis of Haleon plc (HLNCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haleon plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Estre Ambiental, Inc. (ESTRF) Income Statement Analysis – Financial Results
- Danske Invest Mix Offensiv Plus (DKIMOPA.CO) Income Statement Analysis – Financial Results
- Orient Cement Limited (ORIENTCEM.BO) Income Statement Analysis – Financial Results
- Alexion Pharmaceuticals, Inc. (AXP.DE) Income Statement Analysis – Financial Results
- China Environmental Technology Holdings Limited (0646.HK) Income Statement Analysis – Financial Results
Haleon plc (HLNCF)
About Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 11.30B | 10.86B | 9.55B | 9.89B | 8.48B |
| Cost of Revenue | 4.34B | 4.28B | 3.60B | 3.98B | 3.68B |
| Gross Profit | 6.96B | 6.58B | 5.95B | 5.91B | 4.80B |
| Gross Profit Ratio | 61.59% | 60.57% | 62.34% | 59.75% | 56.63% |
| Research & Development | 311.00M | 300.00M | 257.00M | 304.00M | 292.00M |
| General & Administrative | 2.27B | 4.48B | 4.09B | 4.22B | 3.60B |
| Selling & Marketing | 2.02B | 2.03B | 1.94B | 0.00 | 0.00 |
| SG&A | 4.29B | 4.48B | 4.09B | 4.22B | 3.60B |
| Other Expenses | 366.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.97B | 4.75B | 4.31B | 4.31B | 3.91B |
| Cost & Expenses | 9.31B | 9.03B | 7.91B | 8.29B | 7.58B |
| Interest Income | 14.00M | 51.00M | 17.00M | 14.00M | 24.00M |
| Interest Expense | 414.00M | 258.00M | 12.00M | 15.00M | 26.00M |
| Depreciation & Amortization | 309.00M | 287.00M | 268.00M | 305.00M | 260.00M |
| EBITDA | 2.35B | 2.18B | 2.21B | 1.91B | 1.17B |
| EBITDA Ratio | 20.80% | 19.92% | 20.44% | 19.26% | 13.87% |
| Operating Income | 2.00B | 1.83B | 1.64B | 1.60B | 897.00M |
| Operating Income Ratio | 17.66% | 16.81% | 17.16% | 16.15% | 10.58% |
| Total Other Income/Expenses | -368.00M | -207.00M | -2.00M | -7.00M | -11.00M |
| Income Before Tax | 1.63B | 1.62B | 1.64B | 1.59B | 886.00M |
| Income Before Tax Ratio | 14.40% | 14.90% | 17.14% | 16.08% | 10.45% |
| Income Tax Expense | 517.00M | 499.00M | 197.00M | 410.00M | 199.00M |
| Net Income | 1.05B | 1.06B | 1.39B | 1.15B | 655.00M |
| Net Income Ratio | 9.28% | 9.76% | 14.56% | 11.58% | 7.72% |
| EPS | 0.11 | 0.11 | 0.15 | 0.12 | 0.07 |
| EPS Diluted | 0.11 | 0.11 | 0.15 | 0.12 | 0.07 |
| Weighted Avg Shares Out | 9.26B | 9.24B | 9.23B | 9.23B | 9.23B |
| Weighted Avg Shares Out (Dil) | 9.26B | 9.24B | 9.23B | 9.23B | 9.23B |
Source: https://incomestatements.info
Category: Stock Reports